Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Hitting out at India’s way of dealing with Intellectual Property Rights (IPR) issues, drug major Novartis has said India is losing investments in research and development from MNCs to China due to lack of an ecosystem that fosters innovation. According to the company, which lost a patent case for its cancer drug Glivec, India needs to have fast track courts to deal with IPR disputes. “The recent cases that we have seen in the area of IPR do not in any way point to an environment that encourages innovation.”
Help employers find you! Check out all the jobs and post your resume.
